Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...

智通财经APP获悉，葛兰素史克(GSK.US)报告称，一项研究表明，其药物 belantamab mafodotin 能够将多发性骨髓瘤患者在首次复发时或复发后的死亡风险降低 42%。该研究正在评估 belantamab mafodotin 与 ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...

GSK今日宣布，其抗体偶联药物（ADC）Blenrep（belantamab mafodotin）在3期临床试验DREAMM-7的预定中期分析中获得了积极结果。该试验评估了Blenrep联合硼替佐 ...

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

The DREAMM-7 trial showed belantamab mafodotin combination significantly improved overall survival in relapsed/refractory multiple myeloma compared to daratumumab-based therapy. The ...